Tfcp2l1-flox Mouse
Common Name
Tfcp2l1-flox
제품 ID
S-CKO-18215
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-81879-Tfcp2l1-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Tfcp2l1-flox Mouse (카탈로그 번호 S-CKO-18215)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Tfcp2l1-flox
품종 계통계통 ID
CKOCMP-81879-Tfcp2l1-B6J-VB
유전자명
제품 ID
S-CKO-18215
유전자 별칭
1810030F05Rik, 4932442M07Rik, Cp2l1, Crtr-1, D930018N21Rik, LBP-9, Tcfcp2l1
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 1
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000027629
NCBI 전사체 ID
NM_023755
타겟 영역
Exon 2
유효 영역 크기
~1.5 kb
유전자 연구 개요
Tfcp2l1, also known as CRTR-1 and LBP-9, is a transcription factor. It is crucial for maintaining the pluripotency and self-renewal of embryonic stem cells [1,3,6,8,9,10]. It is involved in multiple pathways related to cell fate determination and stemness regulation, and is of great biological importance in processes such as development and tissue regeneration [5]. Genetic models, especially KO/CKO mouse models, are valuable tools for studying its functions.
In renal medullary carcinoma, the loss of renal epithelial transcription factor TFCP2L1 is associated with the transformation of thick ascending limb cells into RMC cells, along with the gain of MYC and NFE2L2-associated oncogenic and ferroptosis resistance programs [2]. In hepatocellular carcinoma, knockdown of TFCP2L1 significantly reduced HCC cell proliferation, invasion, etc., while overexpression enhanced these functions, and it promotes the stemness of cancer stem cells through the NANOG/STAT3 pathway [3]. In thyroid cancer, decreased TFCP2L1 expression was associated with malignant clinicopathological characteristics, and its overexpression inhibited cell growth and motility [4]. In lung alveolar regeneration, Tfcp2l1 loss in adult alveolar epithelial type 2 (AT2) cells inhibits self-renewal and enhances AT2-AT1 differentiation during tissue regeneration [5]. In bladder cancer, the CDK1/TFCP2L1/ID2 cascade is involved in regulating bladder carcinogenesis, and TFCP2L1 downregulates ID2 by directly binding to its promoter region [7]. In mouse embryonic fibroblasts, hypoxia-induced Tfcp2l1 expression contributes to immortalization prior to malignant transformation [10].
In conclusion, Tfcp2l1 plays essential roles in maintaining stem cell pluripotency, self-renewal, and in processes like tissue regeneration. Its dysregulation is implicated in various cancers, including renal medullary carcinoma, hepatocellular carcinoma, thyroid cancer, and bladder cancer. Studies using KO/CKO mouse models have been instrumental in revealing its functions in these disease-related biological processes, providing insights into potential therapeutic targets.
References:
1. Kotarba, Grzegorz, Krzywinska, Ewa, Grabowska, Anna I, Taracha, Agnieszka, Wilanowski, Tomasz. 2018. TFCP2/TFCP2L1/UBP1 transcription factors in cancer. In Cancer letters, 420, 72-79. doi:10.1016/j.canlet.2018.01.078. https://pubmed.ncbi.nlm.nih.gov/29410248/
2. Vokshi, Bujamin H, Davidson, Guillaume, Tawanaie Pour Sedehi, Nassim, Davidson, Irwin, Malouf, Gabriel G. 2023. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. In Nature communications, 14, 3034. doi:10.1038/s41467-023-38472-y. https://pubmed.ncbi.nlm.nih.gov/37236926/
3. Qiu, Dongbo, Wang, Tiantian, Xiong, Yi, Zhang, Qi, Jia, Changchang. 2024. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. In Oncogenesis, 13, 33. doi:10.1038/s41389-024-00534-1. https://pubmed.ncbi.nlm.nih.gov/39266516/
4. Zeng, C, Zhang, Y, Lin, C, Li, Y, Guan, H. 2024. TFCP2L1, a potential differentiation regulator, predicts favorable prognosis and dampens thyroid cancer progression. In Journal of endocrinological investigation, 47, 2953-2968. doi:10.1007/s40618-024-02392-5. https://pubmed.ncbi.nlm.nih.gov/38753296/
5. Cardenas-Diaz, Fabian L, Liberti, Derek C, Leach, John P, Morley, Michael P, Morrisey, Edward E. 2023. Temporal and spatial staging of lung alveolar regeneration is determined by the grainyhead transcription factor Tfcp2l1. In Cell reports, 42, 112451. doi:10.1016/j.celrep.2023.112451. https://pubmed.ncbi.nlm.nih.gov/37119134/
6. Sun, Hongwei, You, Yu, Guo, Mengmeng, Zhang, Yan, Ye, Shoudong. 2018. Tfcp2l1 safeguards the maintenance of human embryonic stem cell self-renewal. In Journal of cellular physiology, 233, 6944-6951. doi:10.1002/jcp.26483. https://pubmed.ncbi.nlm.nih.gov/29323720/
7. Heo, Jinbeom, Lee, Jinyoung, Nam, Yun Ji, Son, Jaekyoung, Shin, Dong-Myung. 2022. The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer. In Experimental & molecular medicine, 54, 801-811. doi:10.1038/s12276-022-00786-0. https://pubmed.ncbi.nlm.nih.gov/35729325/
8. Zhang, Yan, Ding, Huiwen, Wang, Xiaoxiao, Gan, Ruoyi, Ye, Shou-Dong. . MK2 promotes Tfcp2l1 degradation via β-TrCP ubiquitin ligase to regulate mouse embryonic stem cell self-renewal. In Cell reports, 37, 109949. doi:10.1016/j.celrep.2021.109949. https://pubmed.ncbi.nlm.nih.gov/34731635/
9. Heo, Jinbeom, Noh, Byeong-Joo, Lee, Seungun, Cho, Yong Mee, Shin, Dong-Myung. 2019. Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis. In EMBO molecular medicine, 12, e10880. doi:10.15252/emmm.201910880. https://pubmed.ncbi.nlm.nih.gov/31709755/
10. Otero-Albiol, D, Santos-Pereira, J M, Lucena-Cacace, A, Yoshida, Y, Carnero, A. 2024. Hypoxia-induced immortalization of primary cells depends on Tfcp2L1 expression. In Cell death & disease, 15, 177. doi:10.1038/s41419-024-06567-z. https://pubmed.ncbi.nlm.nih.gov/38418821/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
